What is the appropriate evaluation and management for skin irritation suspected to be caused by hormonal medications in a 28-year-old woman undergoing in‑vitro fertilization?

Skin Irritation During IVF: Evaluation and Management

This is most likely progesterone hypersensitivity, a rare but increasingly recognized complication of IVF treatment that requires immediate evaluation and specific management to allow continuation of fertility treatment.

Initial Evaluation

Obtain a detailed timeline correlating the skin reaction with progesterone administration during the IVF cycle. Key features to assess:

• Timing: Did symptoms begin after starting exogenous progesterone (typically during luteal phase support)?
• Pattern: Localized reaction at injection/application site versus generalized urticaria or rash
• Severity: Mild skin changes (localized redness, itching) versus systemic symptoms (widespread urticaria, angioedema, respiratory symptoms, hypotension)
• Previous cycles: Any history of cyclical rashes during natural menstrual cycles or prior IVF attempts

Rule out other causes systematically:

• Review all medications for other potential allergens
• Examine for infection (bacterial, fungal, viral)
• Assess for contact dermatitis from topical preparations
• Consider other drug reactions from concurrent IVF medications 1

Diagnostic Confirmation

Skin testing is the gold standard for diagnosis 2, 3:

• Timing: Perform testing at least 6 weeks after complete resolution of the acute reaction 4
• Method: Begin with skin prick testing using injectable progesterone; if negative, proceed to intradermal testing (0.02-0.05 mL of 1% and 10% concentrations) 4
• Reading: Assess at 24-72 hours for delayed reactions 4
• Caution: Intradermal testing itself can trigger anaphylaxis in sensitized patients 3

Management Algorithm

For Mild Reactions (Grade 1)

Localized redness, mild itching, <10% body surface area

Continue IVF cycle with symptomatic treatment 1:

• Topical emollients twice daily
• Mild-to-moderate potency topical corticosteroids (e.g., hydrocortisone cream) twice daily 1, 5
• Oral antihistamines: levocetirizine or cetirizine daily 2, 6
• Avoid skin irritants and mechanical stress 7
• Reassess after 2 weeks

For Moderate Reactions (Grade 2)

10-30% body surface area, significant pruritus, or limiting daily activities

Consider holding progesterone temporarily 1:

• High-potency topical corticosteroids (e.g., clobetasol propionate 0.05%) twice daily 7
• Oral antihistamines at therapeutic doses
• Consider systemic corticosteroids: prednisone 0.5-1 mg/kg tapered over 4 weeks 1
• Coordinate with reproductive endocrinologist before discontinuing progesterone, as this may compromise the IVF cycle

For Severe Reactions (Grade 3) or Anaphylaxis

>30% body surface area with severe symptoms, or systemic involvement

Immediately discontinue progesterone 1:

• Treat anaphylaxis per standard protocols if present
• Prescribe epinephrine auto-injector with written action plan 2
• High-dose systemic corticosteroids: prednisone 1 mg/kg daily 1
• Daily antihistamine prophylaxis 2

Continuing IVF Treatment

Progesterone desensitization is the definitive solution for patients requiring IVF 8:

This is critical because progesterone is essential for luteal phase support and has no alternative in IVF protocols 6, 8. The evidence shows successful desensitization protocols:

• Rapid 8-10 step desensitization protocols administered over several hours
• Increasing doses given every 20 minutes via intravaginal suppositories 8
• Must be performed by physicians experienced in desensitization procedures
• Requires emergency equipment and monitoring
• Desensitization must be repeated with each IVF cycle 8

Alternative approach for future cycles 3:

• High-dose omalizumab has shown success in refractory cases
• Consider for patients planning pregnancy who cannot undergo repeated desensitization

Long-term Management

For confirmed progesterone hypersensitivity:

• Daily prophylactic antihistamines (levocetirizine) to prevent endogenous progesterone reactions 2
• Epinephrine auto-injector for emergency use
• Close monitoring during pregnancy if conception occurs
• Document allergy clearly in medical records

Critical Pitfalls to Avoid

1. Do not dismiss cyclical symptoms: Women reporting rashes during luteal phase or previous IVF cycles require formal evaluation 2, 6
2. Do not perform intradermal testing without preparation: Have emergency equipment ready, as testing itself can trigger anaphylaxis 3
3. Do not discontinue progesterone without consulting reproductive endocrinology: This can compromise the entire IVF cycle 6, 8
4. Do not attempt desensitization without expertise: This requires specialized training and monitoring 8

The increasing use of assisted reproductive technologies has led to more recognized cases of exogenous progesterone hypersensitivity 9, 6. Early recognition allows for appropriate management strategies that can preserve fertility treatment success while ensuring patient safety.